[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$funGmO9xMgtmTwOcqWIbjXrXI-pOr70fk0dXASgvUBDc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":50,"rows":57},"Nemours Children's Clinic",[4],124,false,29,7,15809,4,93,[14,17,20,22,25,27,30,32],{"name":15,"count":16},"Asthma",10,{"name":18,"count":19},"Type 1 Diabetes Mellitus",8,{"name":21,"count":9},"Obesity",{"name":23,"count":24},"Diabetes Mellitus, Type 1",6,{"name":26,"count":11},"Type 1 Diabetes",{"name":28,"count":29},"Idiopathic Short Stature",3,{"name":31,"count":29},"Pediatric Obesity",{"name":33,"count":29},"Spinal Muscular Atrophy",[35,40,45],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT07169136","Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)","2026-12","GLP-1 Receptor Agonists",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT07552766","A Clinical Trial on the Use of Lidocaine Infusion During Surgery for Pediatric Upper Extremity Fractures and Its Impact on Total Perioperative Opioid Requirements","2028-12","Lidocaine",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06946264","Characterization of Bronchodilator Response in Children With Bronchiolitis Using Phenotypic and Genotypic Features","2029-12-31","Albuterol Sulfate, 2.5 Mg\u002F3 mL (0.083%) Inhalation Solution",[51,52,53,54,55,56],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[58,89,114,132,154,181,199,217,243,267,294,312,330,355,373,402,420,448,466,505,523,541,565,589,615,633,651,677,703,731,749,773,797,821,845,872,890,908,941,966,990,1015,1042,1068],{"intervention":44,"totalTrials":59,"cells":60},1,{"EARLY_PHASE1":61,"PHASE1":64,"PHASE2":66,"PHASE3":68,"PHASE4":70,"NA":87},{"trials":62,"activeCount":63},[],0,{"trials":65,"activeCount":63},[],{"trials":67,"activeCount":63},[],{"trials":69,"activeCount":63},[],{"trials":71,"activeCount":59,"soonestReadout":43},[72],{"nctId":41,"briefTitle":42,"status":73,"phases":74,"primaryCompletion":43,"completion":75,"start":76,"enrollment":77,"conditions":78,"interventions":86},"NOT_YET_RECRUITING",[55],"2029-07","2026-05",90,[79,80,81,82,83,84,85],"Fracture Arm","Fracture Closed of Lower End of Forearm, Unspecified","Fracture Elbow","Fracture Fixation","Fracture Fixation, Internal","Fracture Forearm","Fracture Distal Radius",[44],{"trials":88,"activeCount":63},[],{"intervention":49,"totalTrials":59,"cells":90},{"EARLY_PHASE1":91,"PHASE1":93,"PHASE2":95,"PHASE3":97,"PHASE4":110,"NA":112},{"trials":92,"activeCount":63},[],{"trials":94,"activeCount":63},[],{"trials":96,"activeCount":63},[],{"trials":98,"activeCount":59,"soonestReadout":48},[99],{"nctId":46,"briefTitle":47,"status":100,"phases":101,"primaryCompletion":48,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":108},"RECRUITING",[54],"2030-12-31","2022-07-08",400,[106,107],"Bronchiolitis","Bronchodilator Agents",[49,109],"Sodium Chloride 0.9% Inhl 3Ml",{"trials":111,"activeCount":63},[],{"trials":113,"activeCount":63},[],{"intervention":109,"totalTrials":59,"cells":115},{"EARLY_PHASE1":116,"PHASE1":118,"PHASE2":120,"PHASE3":122,"PHASE4":128,"NA":130},{"trials":117,"activeCount":63},[],{"trials":119,"activeCount":63},[],{"trials":121,"activeCount":63},[],{"trials":123,"activeCount":59,"soonestReadout":48},[124],{"nctId":46,"briefTitle":47,"status":100,"phases":125,"primaryCompletion":48,"completion":102,"start":103,"enrollment":104,"conditions":126,"interventions":127},[54],[106,107],[49,109],{"trials":129,"activeCount":63},[],{"trials":131,"activeCount":63},[],{"intervention":39,"totalTrials":59,"cells":133},{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":138,"PHASE3":140,"PHASE4":142,"NA":144},{"trials":135,"activeCount":63},[],{"trials":137,"activeCount":63},[],{"trials":139,"activeCount":63},[],{"trials":141,"activeCount":63},[],{"trials":143,"activeCount":63},[],{"trials":145,"activeCount":59,"soonestReadout":38},[146],{"nctId":36,"briefTitle":37,"status":100,"phases":147,"primaryCompletion":38,"completion":38,"start":148,"enrollment":149,"conditions":150,"interventions":153},[],"2025-09-11",20,[151,152],"Polycystic Ovarian Syndrome in Adolescent Females","Obesity (Disorder)",[39],{"intervention":155,"totalTrials":59,"cells":156},"fluticasone\u002Fsalmeterol 250\u002F50 Dry Powder Inhaler",{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":165,"NA":179},{"trials":158,"activeCount":63},[],{"trials":160,"activeCount":63},[],{"trials":162,"activeCount":63},[],{"trials":164,"activeCount":63},[],{"trials":166,"activeCount":63},[167],{"nctId":168,"briefTitle":169,"status":170,"phases":171,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":176},"NCT02061280","Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial","COMPLETED",[55],"2017-02-17","2013-10",108,[15],[155,177,178],"fluticasone\u002Fsalmeterol 100\u002F50 Dry Powder Inhaler","fluticasone 100mcg Dry Powder Inhaler",{"trials":180,"activeCount":63},[],{"intervention":177,"totalTrials":59,"cells":182},{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":189,"PHASE4":191,"NA":197},{"trials":184,"activeCount":63},[],{"trials":186,"activeCount":63},[],{"trials":188,"activeCount":63},[],{"trials":190,"activeCount":63},[],{"trials":192,"activeCount":63},[193],{"nctId":168,"briefTitle":169,"status":170,"phases":194,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":195,"interventions":196},[55],[15],[155,177,178],{"trials":198,"activeCount":63},[],{"intervention":178,"totalTrials":59,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":215},{"trials":202,"activeCount":63},[],{"trials":204,"activeCount":63},[],{"trials":206,"activeCount":63},[],{"trials":208,"activeCount":63},[],{"trials":210,"activeCount":63},[211],{"nctId":168,"briefTitle":169,"status":170,"phases":212,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":213,"interventions":214},[55],[15],[155,177,178],{"trials":216,"activeCount":63},[],{"intervention":218,"totalTrials":59,"cells":219},"Genotype Guided PPI Dosing",{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":228,"NA":241},{"trials":221,"activeCount":63},[],{"trials":223,"activeCount":63},[],{"trials":225,"activeCount":63},[],{"trials":227,"activeCount":63},[],{"trials":229,"activeCount":63},[230],{"nctId":231,"briefTitle":232,"status":170,"phases":233,"primaryCompletion":234,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":240},"NCT02794844","Implementation of PPI Medication PGX Testing",[55],"2017-01-23","2018-08-31","2016-07-21",28,[239],"Gastroesophageal Reflux",[218],{"trials":242,"activeCount":63},[],{"intervention":244,"totalTrials":59,"cells":245},"albuterol",{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":252,"PHASE4":254,"NA":265},{"trials":247,"activeCount":63},[],{"trials":249,"activeCount":63},[],{"trials":251,"activeCount":63},[],{"trials":253,"activeCount":63},[],{"trials":255,"activeCount":63},[256],{"nctId":257,"briefTitle":258,"status":170,"phases":259,"primaryCompletion":260,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":264},"NCT00940927","Dose-response of Albuterol in Asthmatics",[55],"1994-10","1993-07",81,[15],[244],{"trials":266,"activeCount":63},[],{"intervention":268,"totalTrials":59,"cells":269},"open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER®",{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":276,"PHASE4":278,"NA":292},{"trials":271,"activeCount":63},[],{"trials":273,"activeCount":63},[],{"trials":275,"activeCount":63},[],{"trials":277,"activeCount":63},[],{"trials":279,"activeCount":63},[280],{"nctId":281,"briefTitle":282,"status":283,"phases":284,"primaryCompletion":285,"completion":285,"start":286,"enrollment":63,"conditions":287,"interventions":289},"NCT01108627","Effect of Gly16Arg Polymorphism in ADRB2 Gene on Asthma Control in Children Receiving Long Acting Beta Agonists","WITHDRAWN",[55],"2011-12","2010-10",[288],"Safety of Long Acting Beta Agnoists",[268,290,291],"foradil placebo","foradil",{"trials":293,"activeCount":63},[],{"intervention":290,"totalTrials":59,"cells":295},{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":302,"PHASE4":304,"NA":310},{"trials":297,"activeCount":63},[],{"trials":299,"activeCount":63},[],{"trials":301,"activeCount":63},[],{"trials":303,"activeCount":63},[],{"trials":305,"activeCount":63},[306],{"nctId":281,"briefTitle":282,"status":283,"phases":307,"primaryCompletion":285,"completion":285,"start":286,"enrollment":63,"conditions":308,"interventions":309},[55],[288],[268,290,291],{"trials":311,"activeCount":63},[],{"intervention":291,"totalTrials":59,"cells":313},{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":320,"PHASE4":322,"NA":328},{"trials":315,"activeCount":63},[],{"trials":317,"activeCount":63},[],{"trials":319,"activeCount":63},[],{"trials":321,"activeCount":63},[],{"trials":323,"activeCount":63},[324],{"nctId":281,"briefTitle":282,"status":283,"phases":325,"primaryCompletion":285,"completion":285,"start":286,"enrollment":63,"conditions":326,"interventions":327},[55],[288],[268,290,291],{"trials":329,"activeCount":63},[],{"intervention":331,"totalTrials":59,"cells":332},"Bupivacaine, Dexmedetomidine, Caffeine, Tylenol",{"EARLY_PHASE1":333,"PHASE1":335,"PHASE2":337,"PHASE3":339,"PHASE4":341,"NA":353},{"trials":334,"activeCount":63},[],{"trials":336,"activeCount":63},[],{"trials":338,"activeCount":63},[],{"trials":340,"activeCount":63},[],{"trials":342,"activeCount":63},[343],{"nctId":344,"briefTitle":345,"status":170,"phases":346,"primaryCompletion":347,"completion":347,"start":348,"enrollment":149,"conditions":349,"interventions":351},"NCT05919732","Awake Caudal Catheter vs General Anesthesia",[55],"2018-03-08","2016-03-08",[350],"Inguinal Hernia",[331,352],"Propofol, rocuronium, caffeine, Tylenol, bupivacaine",{"trials":354,"activeCount":63},[],{"intervention":352,"totalTrials":59,"cells":356},{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":365,"NA":371},{"trials":358,"activeCount":63},[],{"trials":360,"activeCount":63},[],{"trials":362,"activeCount":63},[],{"trials":364,"activeCount":63},[],{"trials":366,"activeCount":63},[367],{"nctId":344,"briefTitle":345,"status":170,"phases":368,"primaryCompletion":347,"completion":347,"start":348,"enrollment":149,"conditions":369,"interventions":370},[55],[350],[331,352],{"trials":372,"activeCount":63},[],{"intervention":374,"totalTrials":59,"cells":375},"17 B estradiol orally",{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":382,"PHASE4":384,"NA":400},{"trials":377,"activeCount":63},[],{"trials":379,"activeCount":63},[],{"trials":381,"activeCount":63},[],{"trials":383,"activeCount":63},[],{"trials":385,"activeCount":63},[386],{"nctId":387,"briefTitle":388,"status":170,"phases":389,"primaryCompletion":390,"completion":391,"start":392,"enrollment":393,"conditions":394,"interventions":398},"NCT00837616","Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism",[55],"2012-06","2012-12","2009-01",41,[395,396,397],"Turner Syndrome","Hypogonadism","Premature Ovarian Failure",[374,399],"17 B estradiol",{"trials":401,"activeCount":63},[],{"intervention":399,"totalTrials":59,"cells":403},{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":408,"PHASE3":410,"PHASE4":412,"NA":418},{"trials":405,"activeCount":63},[],{"trials":407,"activeCount":63},[],{"trials":409,"activeCount":63},[],{"trials":411,"activeCount":63},[],{"trials":413,"activeCount":63},[414],{"nctId":387,"briefTitle":388,"status":170,"phases":415,"primaryCompletion":390,"completion":391,"start":392,"enrollment":393,"conditions":416,"interventions":417},[55],[395,396,397],[374,399],{"trials":419,"activeCount":63},[],{"intervention":421,"totalTrials":59,"cells":422},"Dose Response - NS and USP Glycerin - First Intervention",{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":427,"PHASE3":429,"PHASE4":431,"NA":446},{"trials":424,"activeCount":63},[],{"trials":426,"activeCount":63},[],{"trials":428,"activeCount":63},[],{"trials":430,"activeCount":63},[],{"trials":432,"activeCount":63},[433],{"nctId":434,"briefTitle":435,"status":170,"phases":436,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":444},"NCT02435069","A Within Subjects Comparison of Two Antegrade Flushing Regimens in Children",[55],"2017-03-28","2018-03-30","2016-02-09",5,[442,443],"Fecal Incontinence","Neurogenic Bowel",[421,445],"Effectiveness - NS and USP Glycerin - Second Intervention",{"trials":447,"activeCount":63},[],{"intervention":445,"totalTrials":59,"cells":449},{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":456,"PHASE4":458,"NA":464},{"trials":451,"activeCount":63},[],{"trials":453,"activeCount":63},[],{"trials":455,"activeCount":63},[],{"trials":457,"activeCount":63},[],{"trials":459,"activeCount":63},[460],{"nctId":434,"briefTitle":435,"status":170,"phases":461,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":462,"interventions":463},[55],[442,443],[421,445],{"trials":465,"activeCount":63},[],{"intervention":467,"totalTrials":468,"cells":469},"Growth Hormone",2,{"EARLY_PHASE1":470,"PHASE1":472,"PHASE2":474,"PHASE3":476,"PHASE4":501,"NA":503},{"trials":471,"activeCount":63},[],{"trials":473,"activeCount":63},[],{"trials":475,"activeCount":63},[],{"trials":477,"activeCount":63},[478,489],{"nctId":479,"briefTitle":480,"status":170,"phases":481,"primaryCompletion":482,"completion":482,"start":483,"enrollment":484,"conditions":485,"interventions":486},"NCT01248416","Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",[54],"2016-09","2010-11",76,[28],[487,467,488],"Aromatase Inhibitor","Aromatase Inhibitor and Growth Hormone",{"nctId":490,"briefTitle":491,"status":170,"phases":492,"primaryCompletion":493,"completion":494,"start":495,"enrollment":496,"conditions":497,"interventions":499},"NCT00133354","Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys",[53,54],"2006-08","2010-08","2001-11",53,[498],"Hypopituitarism",[500,467],"Arimidex",{"trials":502,"activeCount":63},[],{"trials":504,"activeCount":63},[],{"intervention":487,"totalTrials":59,"cells":506},{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":513,"PHASE4":519,"NA":521},{"trials":508,"activeCount":63},[],{"trials":510,"activeCount":63},[],{"trials":512,"activeCount":63},[],{"trials":514,"activeCount":63},[515],{"nctId":479,"briefTitle":480,"status":170,"phases":516,"primaryCompletion":482,"completion":482,"start":483,"enrollment":484,"conditions":517,"interventions":518},[54],[28],[487,467,488],{"trials":520,"activeCount":63},[],{"trials":522,"activeCount":63},[],{"intervention":488,"totalTrials":59,"cells":524},{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":529,"PHASE3":531,"PHASE4":537,"NA":539},{"trials":526,"activeCount":63},[],{"trials":528,"activeCount":63},[],{"trials":530,"activeCount":63},[],{"trials":532,"activeCount":63},[533],{"nctId":479,"briefTitle":480,"status":170,"phases":534,"primaryCompletion":482,"completion":482,"start":483,"enrollment":484,"conditions":535,"interventions":536},[54],[28],[487,467,488],{"trials":538,"activeCount":63},[],{"trials":540,"activeCount":63},[],{"intervention":542,"totalTrials":59,"cells":543},"17 beta estradiol",{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":548,"PHASE3":550,"PHASE4":561,"NA":563},{"trials":545,"activeCount":63},[],{"trials":547,"activeCount":63},[],{"trials":549,"activeCount":63},[],{"trials":551,"activeCount":63},[552],{"nctId":553,"briefTitle":554,"status":170,"phases":555,"completion":556,"start":557,"enrollment":558,"conditions":559,"interventions":560},"NCT00140998","Estrogen Treatment (Oral vs. Patches) in Turner Syndrome",[54],"2004-06","2001-01",16,[395,396,397],[542],{"trials":562,"activeCount":63},[],{"trials":564,"activeCount":63},[],{"intervention":566,"totalTrials":59,"cells":567},"Omega-3 Fatty Acid",{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":574,"PHASE4":585,"NA":587},{"trials":569,"activeCount":63},[],{"trials":571,"activeCount":63},[],{"trials":573,"activeCount":63},[],{"trials":575,"activeCount":63},[576],{"nctId":577,"briefTitle":578,"status":170,"phases":579,"primaryCompletion":580,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":584},"NCT01027143","Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids",[53,54],"2016-10-22","2010-07",143,[15,21],[566],{"trials":586,"activeCount":63},[],{"trials":588,"activeCount":63},[],{"intervention":590,"totalTrials":59,"cells":591},"Atorvastatin",{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":598,"PHASE4":611,"NA":613},{"trials":593,"activeCount":63},[],{"trials":595,"activeCount":63},[],{"trials":597,"activeCount":63},[],{"trials":599,"activeCount":63},[600],{"nctId":601,"briefTitle":602,"status":170,"phases":603,"primaryCompletion":173,"completion":604,"start":286,"enrollment":605,"conditions":606,"interventions":609},"NCT01236365","Statins in Children With Type 1 Diabetes and Hypercholesterolemia",[54],"2014-11",42,[607,608],"Diabetes Mellitus, Insulin-Dependent","Hypercholesterolemia",[590,610],"Atorvastatin Placebo",{"trials":612,"activeCount":63},[],{"trials":614,"activeCount":63},[],{"intervention":610,"totalTrials":59,"cells":616},{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":629,"NA":631},{"trials":618,"activeCount":63},[],{"trials":620,"activeCount":63},[],{"trials":622,"activeCount":63},[],{"trials":624,"activeCount":63},[625],{"nctId":601,"briefTitle":602,"status":170,"phases":626,"primaryCompletion":173,"completion":604,"start":286,"enrollment":605,"conditions":627,"interventions":628},[54],[607,608],[590,610],{"trials":630,"activeCount":63},[],{"trials":632,"activeCount":63},[],{"intervention":500,"totalTrials":59,"cells":634},{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":641,"PHASE4":647,"NA":649},{"trials":636,"activeCount":63},[],{"trials":638,"activeCount":63},[],{"trials":640,"activeCount":63},[],{"trials":642,"activeCount":63},[643],{"nctId":490,"briefTitle":491,"status":170,"phases":644,"primaryCompletion":493,"completion":494,"start":495,"enrollment":496,"conditions":645,"interventions":646},[53,54],[498],[500,467],{"trials":648,"activeCount":63},[],{"trials":650,"activeCount":63},[],{"intervention":652,"totalTrials":59,"cells":653},"Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]",{"EARLY_PHASE1":654,"PHASE1":656,"PHASE2":658,"PHASE3":671,"PHASE4":673,"NA":675},{"trials":655,"activeCount":63},[],{"trials":657,"activeCount":63},[],{"trials":659,"activeCount":63},[660],{"nctId":661,"briefTitle":662,"status":170,"phases":663,"primaryCompletion":664,"completion":664,"start":665,"enrollment":666,"conditions":667,"interventions":670},"NCT05186415","Contrast Enhanced 3D Echocardiographic Quantification of Right Ventricular Volumes in Repaired CHD",[52,53],"2024-06-25","2022-08-23",25,[668,669],"Tetralogy of Fallot","Pulmonary Insufficiency",[652],{"trials":672,"activeCount":63},[],{"trials":674,"activeCount":63},[],{"trials":676,"activeCount":63},[],{"intervention":678,"totalTrials":59,"cells":679},"Tiotropium Bromide",{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":697,"PHASE4":699,"NA":701},{"trials":681,"activeCount":63},[],{"trials":683,"activeCount":63},[],{"trials":685,"activeCount":63},[686],{"nctId":687,"briefTitle":688,"status":689,"phases":690,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":696},"NCT04990167","Tiotropium vs. Inhaled Corticosteroids in Children With Nonatopic Asthma Pilot Study (TioNAAP)","TERMINATED",[53],"2025-10-31","2022-01-01",11,[695],"Asthma in Children",[678],{"trials":698,"activeCount":63},[],{"trials":700,"activeCount":63},[],{"trials":702,"activeCount":63},[],{"intervention":704,"totalTrials":59,"cells":705},"Pediasure",{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":725,"PHASE4":727,"NA":729},{"trials":707,"activeCount":63},[],{"trials":709,"activeCount":63},[],{"trials":711,"activeCount":63},[712],{"nctId":713,"briefTitle":714,"status":170,"phases":715,"primaryCompletion":716,"completion":717,"start":718,"enrollment":149,"conditions":719,"interventions":723},"NCT00139451","Nutrients and Hormones: Effects in Boys With Disordered Growth",[53],"2007-12","2010-09","2004-05",[720,721,722],"Constitutional Growth Delay","Nutrition Disorders","Growth Disorders",[704,724],"GH",{"trials":726,"activeCount":63},[],{"trials":728,"activeCount":63},[],{"trials":730,"activeCount":63},[],{"intervention":724,"totalTrials":59,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":743,"PHASE4":745,"NA":747},{"trials":734,"activeCount":63},[],{"trials":736,"activeCount":63},[],{"trials":738,"activeCount":63},[739],{"nctId":713,"briefTitle":714,"status":170,"phases":740,"primaryCompletion":716,"completion":717,"start":718,"enrollment":149,"conditions":741,"interventions":742},[53],[720,721,722],[704,724],{"trials":744,"activeCount":63},[],{"trials":746,"activeCount":63},[],{"trials":748,"activeCount":63},[],{"intervention":750,"totalTrials":59,"cells":751},"10 mg tablet of montelukast",{"EARLY_PHASE1":752,"PHASE1":754,"PHASE2":765,"PHASE3":767,"PHASE4":769,"NA":771},{"trials":753,"activeCount":63},[],{"trials":755,"activeCount":63},[756],{"nctId":757,"briefTitle":758,"status":170,"phases":759,"primaryCompletion":760,"completion":761,"start":762,"enrollment":468,"conditions":763,"interventions":764},"NCT01086527","Genotype Stratified Pharmacokinetic Study of Montelukast",[52],"2014-09","2014-12","2010-03",[15],[750],{"trials":766,"activeCount":63},[],{"trials":768,"activeCount":63},[],{"trials":770,"activeCount":63},[],{"trials":772,"activeCount":63},[],{"intervention":774,"totalTrials":59,"cells":775},"Topical Sirolimus",{"EARLY_PHASE1":776,"PHASE1":778,"PHASE2":789,"PHASE3":791,"PHASE4":793,"NA":795},{"trials":777,"activeCount":63},[],{"trials":779,"activeCount":63},[780],{"nctId":781,"briefTitle":782,"status":689,"phases":783,"primaryCompletion":784,"completion":784,"start":785,"enrollment":440,"conditions":786,"interventions":788},"NCT04172922","Topical Rapamycin\u002FSirolimus for Complicated Vascular Anomalies and Other Susceptible Lesions",[52],"2024-02-15","2020-04-01",[787],"Vascular Anomaly",[774],{"trials":790,"activeCount":63},[],{"trials":792,"activeCount":63},[],{"trials":794,"activeCount":63},[],{"trials":796,"activeCount":63},[],{"intervention":798,"totalTrials":59,"cells":799},"Aprotinin",{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":813,"PHASE3":815,"PHASE4":817,"NA":819},{"trials":801,"activeCount":63},[],{"trials":803,"activeCount":63},[804],{"nctId":805,"briefTitle":806,"status":170,"phases":807,"start":808,"enrollment":809,"conditions":810,"interventions":812},"NCT00357851","Can Aprotinin Reduce Pancreatitis After Scoliosis Surgery",[52],"2005-03",120,[811],"Pancreatitis",[798],{"trials":814,"activeCount":63},[],{"trials":816,"activeCount":63},[],{"trials":818,"activeCount":63},[],{"trials":820,"activeCount":63},[],{"intervention":822,"totalTrials":59,"cells":823},"Sitagliptin",{"EARLY_PHASE1":824,"PHASE1":826,"PHASE2":837,"PHASE3":839,"PHASE4":841,"NA":843},{"trials":825,"activeCount":63},[],{"trials":827,"activeCount":63},[828],{"nctId":829,"briefTitle":830,"status":170,"phases":831,"primaryCompletion":832,"completion":832,"start":833,"enrollment":24,"conditions":834,"interventions":836},"NCT01721382","Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis",[52],"2016-06","2012-11",[835],"Cystic Fibrosis",[822],{"trials":838,"activeCount":63},[],{"trials":840,"activeCount":63},[],{"trials":842,"activeCount":63},[],{"trials":844,"activeCount":63},[],{"intervention":846,"totalTrials":59,"cells":847},"IV acetaminophen",{"EARLY_PHASE1":848,"PHASE1":862,"PHASE2":864,"PHASE3":866,"PHASE4":868,"NA":870},{"trials":849,"activeCount":63},[850],{"nctId":851,"briefTitle":852,"status":170,"phases":853,"primaryCompletion":854,"completion":854,"start":855,"enrollment":582,"conditions":856,"interventions":859},"NCT03062488","Emergence Agitation and Pain Scores in Pediatrics When Comparing Single-modal vs Multi-modal Analgesia for ENT Surgery",[51],"2018-07-11","2017-10-03",[857,858],"Emergence Agitation","Pain",[846,860,861],"Fentanyl","PO acetaminophen",{"trials":863,"activeCount":63},[],{"trials":865,"activeCount":63},[],{"trials":867,"activeCount":63},[],{"trials":869,"activeCount":63},[],{"trials":871,"activeCount":63},[],{"intervention":860,"totalTrials":59,"cells":873},{"EARLY_PHASE1":874,"PHASE1":880,"PHASE2":882,"PHASE3":884,"PHASE4":886,"NA":888},{"trials":875,"activeCount":63},[876],{"nctId":851,"briefTitle":852,"status":170,"phases":877,"primaryCompletion":854,"completion":854,"start":855,"enrollment":582,"conditions":878,"interventions":879},[51],[857,858],[846,860,861],{"trials":881,"activeCount":63},[],{"trials":883,"activeCount":63},[],{"trials":885,"activeCount":63},[],{"trials":887,"activeCount":63},[],{"trials":889,"activeCount":63},[],{"intervention":861,"totalTrials":59,"cells":891},{"EARLY_PHASE1":892,"PHASE1":898,"PHASE2":900,"PHASE3":902,"PHASE4":904,"NA":906},{"trials":893,"activeCount":63},[894],{"nctId":851,"briefTitle":852,"status":170,"phases":895,"primaryCompletion":854,"completion":854,"start":855,"enrollment":582,"conditions":896,"interventions":897},[51],[857,858],[846,860,861],{"trials":899,"activeCount":63},[],{"trials":901,"activeCount":63},[],{"trials":903,"activeCount":63},[],{"trials":905,"activeCount":63},[],{"trials":907,"activeCount":63},[],{"intervention":909,"totalTrials":468,"cells":910},"Regular Insulin",{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":917,"PHASE4":919,"NA":921},{"trials":912,"activeCount":63},[],{"trials":914,"activeCount":63},[],{"trials":916,"activeCount":63},[],{"trials":918,"activeCount":63},[],{"trials":920,"activeCount":63},[],{"trials":922,"activeCount":63},[923,932],{"nctId":924,"briefTitle":925,"status":170,"phases":926,"primaryCompletion":927,"completion":928,"start":929,"enrollment":393,"conditions":930,"interventions":931},"NCT00858273","Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B",[56],"2011-03","2011-08","2008-03",[23],[909],{"nctId":933,"briefTitle":934,"status":170,"phases":935,"primaryCompletion":936,"completion":937,"start":938,"enrollment":16,"conditions":939,"interventions":940},"NCT00858897","Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A",[56],"2008-02","2009-02","2007-06",[23],[909],{"intervention":942,"totalTrials":59,"cells":943},"Combination of Dexmedetomidine with Midazolam",{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":950,"PHASE4":952,"NA":954},{"trials":945,"activeCount":63},[],{"trials":947,"activeCount":63},[],{"trials":949,"activeCount":63},[],{"trials":951,"activeCount":63},[],{"trials":953,"activeCount":63},[],{"trials":955,"activeCount":63},[956],{"nctId":957,"briefTitle":958,"status":283,"phases":959,"primaryCompletion":960,"completion":960,"start":960,"enrollment":63,"conditions":961,"interventions":965},"NCT02134327","Effect of Dexmedetomidine Versus Midazolam Versus a Combination of the Two as a Premedication for Children Undergoing Bilateral Myringotomy Tube Insertion",[56],"2014-04",[962,963,964],"Pre Operative Sedation","Mask Acceptance","Post Operative Delerium",[942],{"intervention":967,"totalTrials":59,"cells":968},"Multiple daily injections using insulin glargine + rapid acting analog",{"EARLY_PHASE1":969,"PHASE1":971,"PHASE2":973,"PHASE3":975,"PHASE4":977,"NA":979},{"trials":970,"activeCount":63},[],{"trials":972,"activeCount":63},[],{"trials":974,"activeCount":63},[],{"trials":976,"activeCount":63},[],{"trials":978,"activeCount":63},[],{"trials":980,"activeCount":63},[981],{"nctId":982,"briefTitle":983,"status":170,"phases":984,"primaryCompletion":985,"completion":985,"start":986,"enrollment":987,"conditions":988,"interventions":989},"NCT00357890","Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)",[56],"2014-10","2005-12",12,[607],[967],{"intervention":991,"totalTrials":59,"cells":992},"Metformin",{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":999,"PHASE4":1001,"NA":1003},{"trials":994,"activeCount":63},[],{"trials":996,"activeCount":63},[],{"trials":998,"activeCount":63},[],{"trials":1000,"activeCount":63},[],{"trials":1002,"activeCount":63},[],{"trials":1004,"activeCount":63},[1005],{"nctId":1006,"briefTitle":1007,"status":170,"phases":1008,"primaryCompletion":1009,"completion":1010,"start":1011,"enrollment":1012,"conditions":1013,"interventions":1014},"NCT00139477","Study of Serum Markers for Cardiovascular Risk in Obese Youth and Impact of Lifestyle and Medication Intervention",[56],"2009-05","2011-09","2003-11",66,[21],[991],{"intervention":1016,"totalTrials":59,"cells":1017},"ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate",{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1024,"PHASE4":1026,"NA":1028},{"trials":1019,"activeCount":63},[],{"trials":1021,"activeCount":63},[],{"trials":1023,"activeCount":63},[],{"trials":1025,"activeCount":63},[],{"trials":1027,"activeCount":63},[],{"trials":1029,"activeCount":63},[1030],{"nctId":1031,"briefTitle":1032,"status":170,"phases":1033,"primaryCompletion":1034,"completion":1034,"start":1035,"enrollment":1036,"conditions":1037,"interventions":1041},"NCT04577417","Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD",[],"2022-06-15","2020-09-13",70,[1038,1039,1040],"Attention Deficit Hyperactivity Disorder","Attention Deficit Disorder","Attention Deficit Disorder With Hyperactivity",[1016],{"intervention":1043,"totalTrials":59,"cells":1044},"Somatropin",{"EARLY_PHASE1":1045,"PHASE1":1047,"PHASE2":1049,"PHASE3":1051,"PHASE4":1053,"NA":1055},{"trials":1046,"activeCount":63},[],{"trials":1048,"activeCount":63},[],{"trials":1050,"activeCount":63},[],{"trials":1052,"activeCount":63},[],{"trials":1054,"activeCount":63},[],{"trials":1056,"activeCount":63},[1057],{"nctId":1058,"briefTitle":1059,"status":170,"phases":1060,"primaryCompletion":1061,"completion":1062,"start":1063,"enrollment":1064,"conditions":1065,"interventions":1067},"NCT04020913","Skeletal Muscle Effects of GH in Boys",[],"2025-09-30","2025-10-30","2019-07-22",45,[1066,28],"Growth Hormone Deficiency",[1043],{"intervention":1069,"totalTrials":59,"cells":1070},"Glutamine vs. Placebo",{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1077,"PHASE4":1079,"NA":1081},{"trials":1072,"activeCount":63},[],{"trials":1074,"activeCount":63},[],{"trials":1076,"activeCount":63},[],{"trials":1078,"activeCount":63},[],{"trials":1080,"activeCount":63},[],{"trials":1082,"activeCount":63},[1083],{"nctId":1084,"briefTitle":1085,"status":170,"phases":1086,"primaryCompletion":1087,"completion":1087,"start":1088,"enrollment":1089,"conditions":1090,"interventions":1097},"NCT03199638","Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes",[56],"2017-06-30","2016-04-01",14,[23,1091,1092,1093,1094,1095,1096],"Autoimmune Diseases","Diabetes Mellitus","Endocrine System Diseases","Glucose Metabolism Disorders","Immune System Diseases","Metabolic Diseases",[1069]]